{"id":3516,"date":"2014-01-03T16:14:25","date_gmt":"2014-01-03T16:14:25","guid":{"rendered":"\/?p=3516"},"modified":"2014-01-03T16:15:10","modified_gmt":"2014-01-03T16:15:10","slug":"easton-pharmaceuticals-inc-otcmktseaph-spikes-thanks-to-marijuana-hype","status":"publish","type":"post","link":"\/articles\/easton-pharmaceuticals-inc-otcmktseaph-spikes-thanks-to-marijuana-hype\/","title":{"rendered":"Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH) Spikes Thanks To Marijuana Hype"},"content":{"rendered":"

\"1EAPHchart.png\"Apparently the current industry upswing caused by the first legal sale of marijuana for recreational use in Colorado is having a bigger impact than we thought. Even companies like Easton Pharmaceuticals, Inc (OTCMKTS:EAPH<\/a>) have started to attract attention once again and in yesterday’s session their stock simply exploded.  <\/p>\n

<\/p>\n
EAPH<\/a> added more than 68% to close the day at $0.0027. But what was even more impressive was the traded volume – 133 million shares got exchanged throughout the day resulting in a dollar value of $318 thousand. For comparison at the end of last week just 560 thousand shares got traded.<\/div>\n
<\/div>\n
If you have read some of our previous articles about the company you would know that for more than 15 years EAPH<\/a> have been unsuccessfully trying to market their VIORRA gel used to treat female sexual arousal disorder. The company hasn’t given up on their flagship product but has been looking around for something else to do. Back in June they announced intention to enter the medical marijuana sector. We don’t know if they have been able to achieve any kind of progress with this plan as the latest PR regarding it came on October 4 and detailed that EAPH<\/a> will be seeking a distributorship license in Canada.<\/div>\n
It may very well be possible that EAPH<\/a> have scrapped the whole idea because their recent plans have all been connected with the experimental cancer drug “XILIVE”. EAPH<\/a> bought a 10% ownership of the drug and have a 12 month option to buy the rest. Although the drug has been in development for 7 years very little information can be found on the internet about it outside of EAPH<\/a>‘s own PR articles. Currently EAPH<\/a> are looking to start “some form of early stage clinical trial testing program”, in their own words, but how likely that is up to you to decide. <\/div>\n
At the start of December the quarterly report for the period ending September 30 was filed. In it EAPH<\/a> revealed the following financial results: <\/div>\n
\n